Drug intelligence / Profile preview

PRO-571

Development stage: Unknown
Lead developer: Kowa Pharmaceuticals America
Modality: Small Molecules
Administration: Oral

Overview

**PRO-571** is a patent-protected tablet formulation of diclofenac potassium combined with potassium bicarbonate, designed for rapid and consistent absorption leading to faster and higher peak blood concentrations compared to other diclofenac dosage forms. This non-steroidal anti-inflammatory drug (NSAID) targets the broader acute pain market. It was licensed by Kowa Pharmaceuticals America from Applied Pharma Research and divested to Nautilus in 2009 while entering late-stage clinical trials.[1][3]

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on PRO-571.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-571.

Explore the full profile